Coexistence of systemic lupus erythematosus, tuberous sclerosis and aggressive natural killer-cell leukaemia: Coincidence or correlated?

Lupus

Volumn 25, Issue 7, 2016, Pages 766-771

  Olde Bekkink, M ^a   Ahmed Ousenkova, Y M ^a   Netea, M G ^a   Van Der Velden, W J ^a   Berden, J H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Haematological changes; nephritis; systemic lupus erythematosus; tuberous sclerosis

Indexed keywords

ANTIBIOTIC AGENT; ASPARAGINASE; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENALAPRIL; HYDROCORTISONE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; MEPREDNISONE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGGRESSIVE NK CELL LEUKEMIA; ARTICLE; CASE REPORT; CHROMOSOME ANALYSIS; DISCOID LUPUS ERYTHEMATOSUS; DISEASE ACTIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; FEMALE; FEVER; HEMOLYTIC ANEMIA; HEREDITY; HUMAN; LOW DRUG DOSE; NEPHROTIC SYNDROME; PALLIATIVE THERAPY; PRIORITY JOURNAL; RARE DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TUBEROUS SCLEROSIS; BONE MARROW; COMPLICATION; KIDNEY; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY;

ADULT; BONE MARROW; FEMALE; HUMANS; KIDNEY; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; LUPUS ERYTHEMATOSUS, DISCOID; LUPUS ERYTHEMATOSUS, SYSTEMIC; MAGNETIC RESONANCE IMAGING; TUBEROUS SCLEROSIS;

EID: 84966667313     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203316636466     Document Type: Article

References (32)

1. Pettersson T, Pukkala E, Teppo L, Friman C,. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 1992; 51: 437-439.
2. Ogata A, Kitano M, Fukamizu M, Hamano T, Sano H,. Increased serum interleukin-18 in a patient with systemic lupus erythematosus and T-cell large granular lymphocytic leukemia. Mod Rheumatol 2004; 14: 267-270.
3. Bernatsky S, Ramsey-Goldman R, Joseph L, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis 2014; 73: 138-142.
4. Ramsey-Goldman R, Bernatsky S, Clarke A,. Dialogue: what can we learn about the relationship between systemic lupus erythematosus and haematological malignancies from linking disease registries? Lupus Sci Med 2014; 1: e000068-e000068.
5. Curatolo P, Bombardieri R, Jozwiak S,. Tuberous sclerosis. Lancet 2008; 372: 657-668.
6. Northrup H, Krueger DA,. International Tuberous Sclerosis Complex Consensus G. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013; 49: 243-254.
7. Fernandez D, Perl A,. mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus? Discov Med 2010; 9: 173-178.
8. Osborne JP, Fryer A, Webb D,. Epidemiology of tuberous sclerosis. Ann NY Acad Sci 1991; 615: 125-127.
9. Danchenko N, Satia JA, Anthony MS,. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006; 15: 308-318.
10. Pons-Estel GJ, Alarcon GS, Scofield L, Reinlib L, Cooper GS,. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthr Rheum 2010; 39: 257-268.
11. Lima M,. Aggressive mature natural killer cell neoplasms: from epidemiology to diagnosis. Orphanet J Rare Dis 2013; 8: 95-95.
12. van den Reek JM, van Lumig PP, Janssen M, et al. Increased incidence of squamous cell carcinoma of the skin after long-term treatment with azathioprine in patients with auto-immune inflammatory rheumatic diseases. J Eur Acad Dermatol Venereol 2014; 28: 27-33.
13. Perkovic S, Basic-Kinda S, Gasparovic V, et al. Epstein-Barr virus-negative aggressive natural killer-cell leukaemia with high P-glycoprotein activity and phosphorylated extracellular signal-regulated protein kinases 1 and 2. Hematol Rep 2012; 4: e16-e16.
14. Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 1481-1490.
15. Leblanc F, Zhang D, Liu X, Loughran TP,. Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets. Future Oncol 2012; 8: 787-801.
16. Suzuki R, Suzumiya J, Nakamura S, et al. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 2004; 18: 763-770.
17. Wong CK, Ho CY, Li EK, Lam CW,. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000; 9: 589-593.
18. Karube K, Nakagawa M, Tsuzuki S, et al. Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood 2011; 118: 3195-3204.
19. McPhee CG, Sproule TJ, Shin DM, et al. MHC class I family proteins retard systemic lupus erythematosus autoimmunity and B cell lymphomagenesis. J Immunol 2011; 187: 4695-4704.
20. Hanlon P, Avenell A, Aucott L, Vickers MA,. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus. Arthritis Res Ther 2014; 16: R3-R3.
21. Draborg AH, Jacobsen S, Westergaard M, et al. Reduced response to Epstein-Barr virus antigens by T-cells in systemic lupus erythematosus patients. Lupus Sci Med 2014; 1: e000015-e000015.
22. Ko YH, Park S, Kim K, Kim SJ, Kim WS,. Aggressive natural killer cell leukemia: is Epstein-Barr virus negativity an indicator of a favorable prognosis? Acta Haematol 2008; 120: 199-206.
23. Inoki K, Corradetti MN, Guan KL,. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005; 37: 19-24.
24. Singh N, Birkenbach M, Caza T, Perl A, Cohen PL,. Tuberous sclerosis and fulminant lupus in a young woman. J Clin Rheumatol 2013; 19: 134-137.
25. Schade AE, Powers JJ, Wlodarski MW, Maciejewski JP,. Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis. Blood 2006; 107: 4834-4840.
26. Kawada J, Ito Y, Iwata S, et al. mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. Clin Cancer Res 2014; 20: 5412-5422.
27. Steelman LS, Abrams SL, Whelan J, et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008; 22: 686-707.
28. O'Shea JJ, Holland SM, Staudt LM,. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013; 368: 161-170.
29. Bouchekioua A, Scourzic L, de Wever O, et al. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia 2014; 28: 338-348.
30. Koo GC, Tan SY, Tang T, et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov 2012; 2: 591-597.
31. Jerez A, Clemente MJ, Makishima H, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 2012; 120: 3048-3057.
32. Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007; 357: 977-986.